Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Molecular Mechanisms of Pharmacological Action: early-phase trial registry
3 of 3 indexed Molecular Mechanisms of Pharmacological Action trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Molecular Mechanisms of Pharmacological Action: 3 US clinical trials tracked, 3 recruiting.
Molecular Mechanisms of Pharmacological Action is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Yana Najjar, running 1 of these trials.
Enrollment posture brief
Registry condition molecular-mechanisms-of-pharmacological-action
OPEN 3 | RECR 100% | LATE 1 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Molecular Mechanisms of Pharmacological Action lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Molecular Mechanisms of Pharmacological Action on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Molecular Mechanisms of Pharmacological Action is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
Merz North America
NCT07122193
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
Yana Najjar
NCT04572451
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
National Institute of Mental Health (NIMH)
NCT06511908
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Molecular Mechanisms of Pharmacological Action records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Molecular Mechanisms of Pharmacological Action trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Molecular Mechanisms of Pharmacological Action page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Molecular Mechanisms of Pharmacological Action trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Yana Najjar sponsors the most Molecular Mechanisms of Pharmacological Action trials on record, review their full trial history before evaluating a specific study. See Yana Najjar's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Molecular Mechanisms of Pharmacological Action condition card totals 3 registered trials; most-linked intervention (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg); top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.